Condition: Ocular Hypertension · Suspect Glaucoma · Sponsor: University of Maryland, Baltimore
The goal of this clinical trial is to compare participants treated with latanoprost to those treated with Rocklatan (netarsudil/latanoprost) to determine whether the addition of netarsudil results in greater improvements in episcleral venous blood flow in adults with glaucoma or ocular hypertension. Episcleral venous blood flow will be measured using erythrocyte-mediated angiography (EMA) and laser speckle contrast imaging (LSCI). The main questions this study aims to answer are: * Does Rocklatan produce greater increases in episcleral venous blood flow than latanoprost alone? * Can EMA and LSCI reliably detect changes in episcleral venous blood flow following treatment with these medications? Participants will: * Be randomized to receive either latanoprost or Rocklatan * Undergo imaging of the episcleral veins using EMA and LSCI before, during, and after treatment, and * Complete study visits that include standard ophthalmic examinations and intraocular pressure measurements. Hypothesis: The investigators hypothesize that latanoprost, which primarily increases uveoscleral outflow, will not significantly affect the distal episcleral circulation. In contrast, Rocklatan, through its netarsudil component, is expected to produce measurable increases in episcleral venous flow.
This description comes directly from the study's public registry record.
Osamah Saeedi, MD · (410) 328-5929 · osaeedi@som.umaryland.edu
Zaina L Maharoof, BS · (667) 214-1463 · eyeresearch@som.umaryland.edu
Always discuss trial participation with your own doctor first.
| University of Maryland Medical Center | Baltimore, Maryland, United States | Recruiting |
| University Physicians Inc. | Baltimore, Maryland, United States | Recruiting |
| UM Faculty Physicians, Inc. | 5900 Waterloo Crossing | Columbia, Maryland, United States | Recruiting |
| Maryland Eye Consultants and Surgeons | Silver Spring, Maryland, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04401982